
Simulated Trial: 1; Number Enrolled: 40
Pr(Best > Cntrl on Penumbra Change) = 0.999
Pr(Phase III Success on Weighted MRS) = 0.689
Sample Size
0
10
20
30
40
50
60
70
Mean Change in Penumbra Outcome
0
5
10
15
20
25
30
Cntrl
Dose1
Dose2
Dose3
Pr(Best)
0.0241
0.2714
0.7045


Simulated Trial: 1; Number Enrolled: 40
Pr(Best > Cntrl on MRS) = 0.9532
Pr(Phase III Success on Weighted MRS) = 0.689
Sample Size
0
10
20
30
40
50
60
70
Utility−Weighted MRS
0.0
0.2
0.4
0.6
0.8
1.0
Cntrl
Dose1
Dose2
Dose3
Pr(Best)
0.0366
0.0364
0.927


Simulated Trial: 1; Number Enrolled: 80
Pr(Best > Cntrl on Penumbra Change) = 1
Pr(Phase III Success on Weighted MRS) = 0.692
Sample Size
0
10
20
30
40
50
60
70
Mean Change in Penumbra Outcome
0
5
10
15
20
25
30
Cntrl
Dose1
Dose2
Dose3
Pr(Best)
0.0311
0.2209
0.748


Simulated Trial: 1; Number Enrolled: 80
Pr(Best > Cntrl on MRS) = 0.993
Pr(Phase III Success on Weighted MRS) = 0.692
Sample Size
0
10
20
30
40
50
60
70
Utility−Weighted MRS
0.0
0.2
0.4
0.6
0.8
1.0
Cntrl
Dose1
Dose2
Dose3
Pr(Best)
0.2118
0.0188
0.7694


Simulated Trial: 1; Number Enrolled: 120
Pr(Best > Cntrl on Penumbra Change) = 1
Pr(Phase III Success on Weighted MRS) = 0.778
Sample Size
0
10
20
30
40
50
60
70
Mean Change in Penumbra Outcome
0
5
10
15
20
25
30
Cntrl
Dose1
Dose2
Dose3
Pr(Best)
0.0229
0.0756
0.9015


Simulated Trial: 1; Number Enrolled: 120
Pr(Best > Cntrl on MRS) = 0.9997
Pr(Phase III Success on Weighted MRS) = 0.778
Sample Size
0
10
20
30
40
50
60
70
Utility−Weighted MRS
0.0
0.2
0.4
0.6
0.8
1.0
Cntrl
Dose1
Dose2
Dose3
Pr(Best)
0.0756
0.0186
0.9058


Simulated Trial: 1; Number Enrolled: 150
Pr(Best > Cntrl on Penumbra Change) = 1
Pr(Phase III Success on Weighted MRS) = 1
Sample Size
0
10
20
30
40
50
60
70
Mean Change in Penumbra Outcome
0
5
10
15
20
25
30
Cntrl
Dose1
Dose2
Dose3
Pr(Best)
0.0159
0.057
0.9271


Simulated Trial: 1; Number Enrolled: 150
Pr(Best > Cntrl on MRS) = 1
Pr(Phase III Success on Weighted MRS) = 1
Sample Size
0
10
20
30
40
50
60
70
Utility−Weighted MRS
0.0
0.2
0.4
0.6
0.8
1.0
Cntrl
Dose1
Dose2
Dose3
Pr(Best)
0.0472
0.0075
0.9453


Simulated Trial: 2; Number Enrolled: 40
Pr(Best > Cntrl on Penumbra Change) = 1
Pr(Phase III Success on Weighted MRS) = 0.9
Sample Size
0
10
20
30
40
50
60
70
Mean Change in Penumbra Outcome
0
5
10
15
20
25
30
Cntrl
Dose1
Dose2
Dose3
Pr(Best)
0.0072
0.1469
0.8459


Simulated Trial: 2; Number Enrolled: 40
Pr(Best > Cntrl on MRS) = 0.9985
Pr(Phase III Success on Weighted MRS) = 0.9
Sample Size
0
10
20
30
40
50
60
70
Utility−Weighted MRS
0.0
0.2
0.4
0.6
0.8
1.0
Cntrl
Dose1
Dose2
Dose3
Pr(Best)
0.1634
0.4971
0.3395


Simulated Trial: 2; Number Enrolled: 80
Pr(Best > Cntrl on Penumbra Change) = 1
Pr(Phase III Success on Weighted MRS) = 0.781
Sample Size
0
10
20
30
40
50
60
70
Mean Change in Penumbra Outcome
0
5
10
15
20
25
30
Cntrl
Dose1
Dose2
Dose3
Pr(Best)
0.0041
0.602
0.3939


Simulated Trial: 2; Number Enrolled: 80
Pr(Best > Cntrl on MRS) = 0.9817
Pr(Phase III Success on Weighted MRS) = 0.781
Sample Size
0
10
20
30
40
50
60
70
Utility−Weighted MRS
0.0
0.2
0.4
0.6
0.8
1.0
Cntrl
Dose1
Dose2
Dose3
Pr(Best)
0.2946
0.1196
0.5858


Simulated Trial: 2; Number Enrolled: 120
Pr(Best > Cntrl on Penumbra Change) = 1
Pr(Phase III Success on Weighted MRS) = 1
Sample Size
0
10
20
30
40
50
60
70
Mean Change in Penumbra Outcome
0
5
10
15
20
25
30
Cntrl
Dose1
Dose2
Dose3
Pr(Best)
0.0057
0.4264
0.5679


Simulated Trial: 2; Number Enrolled: 120
Pr(Best > Cntrl on MRS) = 1
Pr(Phase III Success on Weighted MRS) = 1
Sample Size
0
10
20
30
40
50
60
70
Utility−Weighted MRS
0.0
0.2
0.4
0.6
0.8
1.0
Cntrl
Dose1
Dose2
Dose3
Pr(Best)
0.3609
0.1706
0.4685


Simulated Trial: 2; Number Enrolled: 150
Pr(Best > Cntrl on Penumbra Change) = 1
Pr(Phase III Success on Weighted MRS) = 0.665
Sample Size
0
10
20
30
40
50
60
70
Mean Change in Penumbra Outcome
0
5
10
15
20
25
30
Cntrl
Dose1
Dose2
Dose3
Pr(Best)
0.0051
0.265
0.7299


Simulated Trial: 2; Number Enrolled: 150
Pr(Best > Cntrl on MRS) = 0.9998
Pr(Phase III Success on Weighted MRS) = 0.665
Sample Size
0
10
20
30
40
50
60
70
Utility−Weighted MRS
0.0
0.2
0.4
0.6
0.8
1.0
Cntrl
Dose1
Dose2
Dose3
Pr(Best)
0.3711
0.0635
0.5654


Simulated Trial: 3; Number Enrolled: 40
Pr(Best > Cntrl on Penumbra Change) = 0.9994
Pr(Phase III Success on Weighted MRS) = 0.446
Sample Size
0
10
20
30
40
50
60
70
Mean Change in Penumbra Outcome
0
5
10
15
20
25
30
Cntrl
Dose1
Dose2
Dose3
Pr(Best)
0.0599
0.2735
0.6666


Simulated Trial: 3; Number Enrolled: 40
Pr(Best > Cntrl on MRS) = 0.9087
Pr(Phase III Success on Weighted MRS) = 0.446
Sample Size
0
10
20
30
40
50
60
70
Utility−Weighted MRS
0.0
0.2
0.4
0.6
0.8
1.0
Cntrl
Dose1
Dose2
Dose3
Pr(Best)
0.4953
0.4603
0.0444


Simulated Trial: 3; Number Enrolled: 80
Pr(Best > Cntrl on Penumbra Change) = 1
Pr(Phase III Success on Weighted MRS) = 0.31
Sample Size
0
10
20
30
40
50
60
70
Mean Change in Penumbra Outcome
0
5
10
15
20
25
30
Cntrl
Dose1
Dose2
Dose3
Pr(Best)
0.006
0.3398
0.6542


Simulated Trial: 3; Number Enrolled: 80
Pr(Best > Cntrl on MRS) = 0.9139
Pr(Phase III Success on Weighted MRS) = 0.31
Sample Size
0
10
20
30
40
50
60
70
Utility−Weighted MRS
0.0
0.2
0.4
0.6
0.8
1.0
Cntrl
Dose1
Dose2
Dose3
Pr(Best)
0.3018
0.6806
0.0176


Simulated Trial: 3; Number Enrolled: 120
Pr(Best > Cntrl on Penumbra Change) = 1
Pr(Phase III Success on Weighted MRS) = 0.191
Sample Size
0
10
20
30
40
50
60
70
Mean Change in Penumbra Outcome
0
5
10
15
20
25
30
Cntrl
Dose1
Dose2
Dose3
Pr(Best)
0.0015
0.283
0.7155


Simulated Trial: 3; Number Enrolled: 120
Pr(Best > Cntrl on MRS) = 0.8705
Pr(Phase III Success on Weighted MRS) = 0.191
Sample Size
0
10
20
30
40
50
60
70
Utility−Weighted MRS
0.0
0.2
0.4
0.6
0.8
1.0
Cntrl
Dose1
Dose2
Dose3
Pr(Best)
0.4549
0.5021
0.043


Simulated Trial: 3; Number Enrolled: 150
Pr(Best > Cntrl on Penumbra Change) = 1
Pr(Phase III Success on Weighted MRS) = 0.233
Sample Size
0
10
20
30
40
50
60
70
Mean Change in Penumbra Outcome
0
5
10
15
20
25
30
Cntrl
Dose1
Dose2
Dose3
Pr(Best)
0.0015
0.2705
0.728


Simulated Trial: 3; Number Enrolled: 150
Pr(Best > Cntrl on MRS) = 0.9489
Pr(Phase III Success on Weighted MRS) = 0.233
Sample Size
0
10
20
30
40
50
60
70
Utility−Weighted MRS
0.0
0.2
0.4
0.6
0.8
1.0
Cntrl
Dose1
Dose2
Dose3
Pr(Best)
0.4892
0.3939
0.1169


Simulated Trial: 4; Number Enrolled: 40
Pr(Best > Cntrl on Penumbra Change) = 1
Pr(Phase III Success on Weighted MRS) = 0.031
Sample Size
0
10
20
30
40
50
60
70
Mean Change in Penumbra Outcome
0
5
10
15
20
25
30
Cntrl
Dose1
Dose2
Dose3
Pr(Best)
0.0553
0.4664
0.4783


Simulated Trial: 4; Number Enrolled: 40
Pr(Best > Cntrl on MRS) = 0.202
Pr(Phase III Success on Weighted MRS) = 0.031
Sample Size
0
10
20
30
40
50
60
70
Utility−Weighted MRS
0.0
0.2
0.4
0.6
0.8
1.0
Cntrl
Dose1
Dose2
Dose3
Pr(Best)
0.496
0.4773
0.0267


Simulated Trial: 4; Number Enrolled: 80
Pr(Best > Cntrl on Penumbra Change) = 1
Pr(Phase III Success on Weighted MRS) = 0.061
Sample Size
0
10
20
30
40
50
60
70
Mean Change in Penumbra Outcome
0
5
10
15
20
25
30
Cntrl
Dose1
Dose2
Dose3
Pr(Best)
0.0135
0.1768
0.8097


Simulated Trial: 4; Number Enrolled: 80
Pr(Best > Cntrl on MRS) = 0.398
Pr(Phase III Success on Weighted MRS) = 0.061
Sample Size
0
10
20
30
40
50
60
70
Utility−Weighted MRS
0.0
0.2
0.4
0.6
0.8
1.0
Cntrl
Dose1
Dose2
Dose3
Pr(Best)
0.0117
0.6712
0.3171


Simulated Trial: 4; Number Enrolled: 120
Pr(Best > Cntrl on Penumbra Change) = 1
Pr(Phase III Success on Weighted MRS) = 0.257
Sample Size
0
10
20
30
40
50
60
70
Mean Change in Penumbra Outcome
0
5
10
15
20
25
30
Cntrl
Dose1
Dose2
Dose3
Pr(Best)
0.0149
0.1355
0.8496


Simulated Trial: 4; Number Enrolled: 120
Pr(Best > Cntrl on MRS) = 0.9017
Pr(Phase III Success on Weighted MRS) = 0.257
Sample Size
0
10
20
30
40
50
60
70
Utility−Weighted MRS
0.0
0.2
0.4
0.6
0.8
1.0
Cntrl
Dose1
Dose2
Dose3
Pr(Best)
0.0101
0.3063
0.6836


Simulated Trial: 4; Number Enrolled: 150
Pr(Best > Cntrl on Penumbra Change) = 1
Pr(Phase III Success on Weighted MRS) = 0.206
Sample Size
0
10
20
30
40
50
60
70
Mean Change in Penumbra Outcome
0
5
10
15
20
25
30
Cntrl
Dose1
Dose2
Dose3
Pr(Best)
0.0121
0.0613
0.9266


Simulated Trial: 4; Number Enrolled: 150
Pr(Best > Cntrl on MRS) = 0.8946
Pr(Phase III Success on Weighted MRS) = 0.206
Sample Size
0
10
20
30
40
50
60
70
Utility−Weighted MRS
0.0
0.2
0.4
0.6
0.8
1.0
Cntrl
Dose1
Dose2
Dose3
Pr(Best)
0.0115
0.2696
0.7189